Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.

@article{Johnson2015TalimogeneL,
  title={Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.},
  author={Douglas B. Johnson and Igor J. Puzanov and Mark C. Kelley},
  journal={Immunotherapy},
  year={2015},
  volume={7 6},
  pages={611-9}
}
Melanoma often spreads to cutaneous or subcutaneous sites that are amenable to direct, intralesional injection. As such, developing effective injectable agents has been of considerable interest. Talimogene laherperepvec (T-VEC) is an injectable modified oncolytic herpes virus being developed for the treatment of advanced melanoma. Pre-clinical studies have shown that T-VEC preferentially infects melanoma cells and exerts antitumor activity through directly mediating cell death and by augmenting… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Abstract 2939: CAVATAK-mediated oncolytic immunotherapy in advanced melanoma patients

  • RH Andtbacka, DR Shafren, M Grose, L Post, J. Weisberg
  • Cancer Res
  • 2014

Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in Phase II study PV-10-MM-02

  • SS Agarwala, JF Thompson, BM Smithers, MI Ross, CR Scoggins
  • J. Clin. Oncol
  • 2014

Similar Papers

Loading similar papers…